Causes of death in pediatric patients vertically infected by the human immunodeficiency virus type 1 in Madrid, Spain, from 1982 to mid-2009

Pediatric Infectious Disease Journal

Volumn 30, Issue 6, 2011, Pages 495-500

  Palladino, Claudia ^a   Climent, Francisco J ^b   José, M Isabel De ^b   Jimenez De Ory, Santiago ^a   Bellón, Jose María ^a   Guillén, Sara ^c   Gurbindo, M Dolores ^d,e   González Tomé, Isabel ^b   Mellado, M José ^f   Martínez Pérez, Jorge ^b   Calvo, Cristina ^g   Ramos, José Tomás ^c   Muñoz Fernández, M Ángeles ^h  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^d HOSPITAL MATERNO INFANTIL GREGORIO MARAÑÓN   (Spain)

^e CSIC   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^h HOSPITAL SEVERO OCHOA   (Spain)

Author keywords

adolescents; causes of death; children; HAART; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CHILD; CHILDHOOD MORTALITY; COMORBIDITY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; MAJOR CLINICAL STUDY; OPPORTUNISTIC INFECTION; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SPAIN; VERTICAL TRANSMISSION;

EID: 79958016577     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318211399f     Document Type: Article

References (40)

1. Patel K, Hernan MA, Williams PL, et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis. 2008;46:507-515. (Pubitemid 351263487)
2. Judd A, Doerholt K, Tookey PA, et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis. 2007;45:918-924. (Pubitemid 47580389)
3. Reddi A, Leeper SC, Grobler AC, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr. 2007;7:13.
4. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;44:599-604. (Pubitemid 46233267)
5. Langston C, Cooper ER, Goldfarb J, et al. Human immunodeficiency virus-related mortality in infants and children: data from the pediatric pulmonary and cardiovascular complications of vertically transmitted HIV (P(2)C(2)) Study. Pediatrics. 2001;107:328-338. (Pubitemid 32121249)
6. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48:590-598.
7. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41:194-200.
8. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27-34. (Pubitemid 44306484)
9. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med. 2005;6:99-106. (Pubitemid 40425973)
10. Mocroft A, Brettle R, Kirk O, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS. 2002;16:1663-1671. (Pubitemid 34921112)
11. Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Vigilancia epidemiolo ́gica del SIDA en España. Registro nacional de casos de SIDA 2009;1. Available at: http://www.msc.es/ciudadanos/enfLesiones/ enf Transmisibles/sida/ vigilancia/SPNSInforme30Jun2009.pdf. Accessed December 15, 2009.
12. Sistema de Información Sanitaria del Sistema Nacional de Salud. Series 1981-2005: Mortalidad por causa de muerte, España y comunidades autónomas. Available at: http://www.msc.es/estadEstudios/estadisticas/ estadisticas/est Ministerio/mortalidad/seriesTablas.htm. Accessed January 15, 2010.
13. Palladino C, Bellon JM, Jarrin I, et al. Impact of highly active antiretroviral therapy (HAART) on AIDS and death in a cohort of vertically HIV type 1-infected children: 1980-2006. AIDS Res Hum Retroviruses. 2009;25: 1091-1097.
14. Garcia-Merino I, de Las Cuevas N, Jimenez JL, et al. The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology. 2009; 6:27.
15. CDC. Revised classification system for HIV-1 infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19. Available at: http://www.cdc.gov/mmwr/preview/ mmwrhtml/00018871.htm. Accessed March 23, 2010.
16. CDC. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR CDC Surveill Summ. 1994;43:1-10. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/ 00032890.htm. Accessed March 23, 2010.
17. Dzwonek AB, Lawson MS, Cole TJ, et al. Body fat changes and lipodystrophy in HIV-infected children: impact of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2006;43:121-123. (Pubitemid 44306499)
18. Zareba KM, Lavigne JE, Lipshultz SE. Cardiovascular effects of HAART in infants and children of HIV-infected mothers. Cardiovasc Toxicol. 2004;4:271-279. (Pubitemid 39382989)
19. Brady MT, Oleske JM, Williams PL, et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr. 2010;53:86-94.
20. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528. (Pubitemid 33144917)
21. Selik RM, Lindegren ML. Changes in deaths reported with human immunodeficiency virus infection among United States children less than thirteen years old, 1987 through 1999. Pediatr Infect Dis J. 2003;22:635-641. (Pubitemid 36900211)
22. Martinez E, Milinkovic A, Buira E, et al. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. HIV Med. 2007;8:251-258. (Pubitemid 46695372)
23. Kaplan JE, Sepkowitz K, Masur H, et al. Opportunistic infections in persons with HIV or other immunocompromising conditions. Emerg Infect Dis. 2001;7:541. (Pubitemid 32726834)
24. Currier JS, Williams PL, Grimes JM, et al. Incidence rates and risk factors for opportunistic infections in a phase III trial comparing indinavir 1 ZDV 1 3TC to ZDV 1 3TC. In: Program and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections, Foundation for Retrovirology and Human Health; Alexandria, VA; 1998:127. Abstract 257.
25. Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. 2006;296:292-300. (Pubitemid 44079313)
26. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187-195. (Pubitemid 30167436)
27. Kapogiannis BG, Soe MM, Nesheim SR, et al. Trends in bacteremia in the pre-and post-highly active antiretroviral therapy era among HIVinfected children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004). Pediatrics. 2008;121:e1229-e1239.
28. Cotton MF, Wasserman E, Smit J, et al. High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus in nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South Africa. BMC Infect Dis. 2008;8:40.
29. Bliss SJ, O'Brien KL, Janoff EN, et al. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect Dis. 2008;8:67-80. (Pubitemid 351620930)
30. Janoff EN, Breiman RF, Daley CL, et al. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med. 1992;117:314-324.
31. Jaspan HB, Huang LC, Cotton MF, et al. Bacterial disease and antimicrobial susceptibility patterns in HIV-infected, hospitalized children: a retrospective cohort study. PLoS One. 2008;3:e3260.
32. CDC. Revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR Recomm Rep. 1995;44(RR-4):1-11. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00037275. htm. Accessed March 20, 2010.
33. Simonds RJ, Lindegren ML, Thomas P, et al. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group. N Engl J Med. 1995;332:786-790.
34. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(suppl 1):S5-S14.
35. Simpson BJ, Shapiro ED, Andiman WA. Prospective cohort study of children born to human immunodeficiency virus-infected mothers, 1985 through 1997: trends in the risk of vertical transmission, mortality and acquired immunodeficiency syndrome indicator diseases in the era before highly active antiretroviral therapy. Pediatr Infect Dis J. 2000;19:618-624. (Pubitemid 30469768)
36. Gibb DM, Duong T, Tookey PA, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ. 2003;327:1019.
37. Blanco F, Garcia-Benayas T, Jose de la Cruz J, et al. First-line therapy and mitochondrial damage: different nucleosides, different findings. HIV Clin Trials. 2003;4:11-19. (Pubitemid 36336093)
38. Sackoff JE, Hanna DB, Pfeiffer MR, et al. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;145:397-406. (Pubitemid 46768570)
39. Smit C, Geskus R, Walker S, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS. 2006;20:741-749. (Pubitemid 43884302)
40. Novoa AM, de Olalla PG, Clos R, et al. Increase in the non-HIV-related deaths among AIDS cases in the HAART era. Curr HIV Res. 2008;6:77-81. (Pubitemid 351461025)